HomeAMBI • NYSEAMERICAN
add
Ambipar Emergency Response
Previous close
$0.45
Day range
$0.36 - $0.40
Year range
$0.20 - $0.55
Market cap
22.17M USD
Avg Volume
5.52K
P/E ratio
-
Dividend yield
-
Primary exchange
NYSEAMERICAN
Market news
Financials
Income Statement
Revenue
Net income
| (BRL) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 817.26M | 10.36% |
Operating expense | -21.56M | -262.28% |
Net income | -99.58M | -226.98% |
Net profit margin | -12.18 | -196.35% |
Earnings per share | — | — |
EBITDA | 138.17M | -17.75% |
Effective tax rate | -34.76% | — |
Balance Sheet
Total assets
Total liabilities
| (BRL) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 358.43M | -15.32% |
Total assets | 5.80B | 34.60% |
Total liabilities | 3.98B | 34.93% |
Total equity | 1.82B | — |
Shares outstanding | 55.43M | — |
Price to book | 0.02 | — |
Return on assets | 3.94% | — |
Return on capital | 4.63% | — |
Cash Flow
Net change in cash
| (BRL) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -99.58M | -226.98% |
Cash from operations | 110.44M | 35.69% |
Cash from investing | 77.48M | 184.48% |
Cash from financing | -381.16M | -157.73% |
Net change in cash | -82.47M | 5.91% |
Free cash flow | -260.36M | -2,494.33% |
About
Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange. Wikipedia
Founded
Jan 1, 2000
Headquarters
Website
Employees
53
